2 Overall and cause-specific hospitalisation and death after COVID-19 hospitalisation in England:

cohort study in OpenSAFELY using linked primary care, secondary care and death registration data

- 5 Krishnan Bhaskaran PhD^{1*} (corresponding: <u>krishnan.bhaskaran@lshtm.ac.uk</u>), Christopher T Rentsch
- 6 PhD^{1*}, George Hickman BEng^{2*}, William J Hulme PhD^{2*}, Anna Schultze PhD¹, Helen J Curtis DPhil²,
- 7 Kevin Wing PhD¹, Charlotte Warren-Gash PhD¹, Laurie Tomlinson PhD¹, Chris J Bates PhD³, Rohini
- 8 Mathur PhD¹, Brian MacKenna MPharm², Viyaasan Mahalingasivam MRCP¹, Angel Wong PhD¹, Alex J
- 9 Walker PhD², Caroline E Morton MRCGP², Daniel Grint PhD¹, Amir Mehrkar MRCGP², Rosalind M
- 10 Eggo PhD¹, Peter Inglesby MPhil², Ian J Douglas PhD¹, Helen I McDonald PhD¹, Jonathan Cockburn
- 11 BSc³, Elizabeth J Williamson PhD¹, David Evans MPhil², John Parry MRCGP³, Frank Hester BSc³, Sam
- Harper MSc³, Stephen JW Evans MSc¹, Sebastian Bacon BA², Liam Smeeth PhD¹⁺, Ben Goldacre
- 13 MRCPsych²⁺ (* = contributed equally; ⁺ = joint senior authors)
- 14 1 Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine;
- 15 2 The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford,
- 16 UK; 3 The Phoenix Partnership, TPP House, Horsforth, Leeds, UK

ABSTRACT

1

3

4

17

- 19 Background: There is concern about medium to long-term adverse outcomes following acute
- 20 COVID-19, but little relevant evidence exists. We aimed to investigate whether risks of hospital
- 21 admission and death, overall and by specific cause, are raised following discharge from a COVID-19
- 22 hospitalisation.
- 23 Methods and Findings: Working on behalf of NHS-England, we used linked primary care and hospital
- data in OpenSAFELY to compare risks of hospital admission and death, overall and by specific cause,
- 25 between people discharged from COVID-19 hospitalisation (February-December 2020), and (i)
- demographically-matched controls from the 2019 general population; (ii) people discharged from
- 27 influenza hospitalisation in 2017-19. We used Cox regression adjusted for personal and clinical
- 28 characteristics.
- 29 24,673 post-discharge COVID-19 patients, 123,362 general population controls, and 16,058 influenza
- 30 controls were followed for ≤315 days. Overall risk of hospitalisation or death (30968 events) was
- 31 higher in the COVID-19 group than general population controls (adjusted-HR 2.23, 2.14-2.31) but
- 32 similar to the influenza group (adjusted-HR 0.94, 0.91-0.98). All-cause mortality (7439 events) was
- highest in the COVID-19 group (adjusted-HR 4.97, 4.58-5.40 vs general population controls and 1.73,
- 34 1.60-1.87 vs influenza controls). Risks for cause-specific outcomes were higher in COVID-19 survivors
- 35 than general population controls, and largely comparable between COVID-19 and influenza patients.
- 36 However, COVID-19 patients were more likely than influenza patients to be readmitted/die due to
- 37 their initial infection/other lower respiratory tract infection (adjusted-HR 1.37, 1.22-1.54), and to
- 38 experience mental health or cognitive-related admission/death (adjusted-HR 1.36, 1.01-2.83); in
- 39 particular, COVID-19 survivors with pre-existing dementia had higher risk of dementia death. One
- 40 limitation of our study is that reasons for hospitalisation/death may have been misclassified in some
- 41 cases due to inconsistent use of codes.
- 42 Conclusions: People discharged from a COVID-19 hospital admission had markedly higher risks for
- rehospitalisation and death than the general population, suggesting a substantial extra burden on
- 44 healthcare. Most risks were similar to those observed after influenza hospitalisations; but COVID-19
- 45 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

 45 patients riad higher risks of all-cause mortality, readmissions/death due to the initial infection, and
- dementia death, highlighting the importance of post-discharge monitoring.

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in early 2020 and rapidly spread around the world, infecting >140 million people globally. Acute infection can be asymptomatic or mild, but a substantial minority of infected people experience severe COVID-19 requiring hospitalisation, with age being a major risk factor, along with male sex, non-White ethnicity and certain comorbidities. Early in the pandemic, the proportion surviving hospitalisation was around 50-70%, though improved treatment guidelines and the identification of effective therapies such as dexamethasone helped to improve survival rates. There is now a large and growing population of people who have survived a COVID-19 hospitalisation, but little is known about their longer-term health outcomes.

Emerging evidence suggests that a subset of people infected with SARS-CoV-2 can experience health problems for at least several months after the acute phase of their infection, with fatigue, pain, respiratory and cardiovascular symptoms, and mental health and cognitive disturbances being among the problems frequently described under the term "post-acute COVID-19 syndrome";10 however, epidemiological characterisation of such sequelae remains immature. Small descriptive studies of COVID-19 survivors have been suggestive of high incidence of a range of outcomes including respiratory, cardiovascular, and mental-health related, but firm conclusions are difficult due to lack of comparison groups. 11,12 There remains limited evidence about post-COVID sequelae across the full range of health outcomes. One recent study of US Department of Veterans Affairs (VA) data examined a wide range of diagnoses, prescriptions and laboratory abnormalities among 30-day survivors of COVID-19, showing excess risks of several health outcomes in the 6 months following infection, compared with the general VA population.¹³ Whether these findings generalise to the entire US population or other settings remains unclear. Another US study limited to people aged <65 years also found excess risks of a range of clinical outcomes ascertained from health insurance data among people with a record of SARS-CoV-2 infection. 14 A UK study of routinelycollected primary care and hospitalisation data described raised rates of all-cause hospital admission and death among patients discharged following a COVID-19 hospitalisation; the authors also noted raised risks of adverse respiratory and cardiovascular sequalae among the selected outcomes investigated.¹⁵ Only a general population comparator was used, making it difficult to disentangle risks specific to COVID-19 from those associated with hospitalisation more generally; furthermore, a hospitalised cohort is likely to have been more prone to health problems at the outset than the general population comparator group.

To strengthen the evidence base in this important emerging area, we therefore aimed to investigate the incidence of subsequent hospital admission and death, both overall and from a wide range of specific causes, following a COVID-19 hospitalisation in England. We aimed to compare post-COVID risks with two separate comparison groups: (i) the general population, and (ii) people hospitalised for influenza prior to the current pandemic.

Methods

89

90

91

92

93

94

95

96 97

98

99

100

101102

103104

105

106

107

108

109

110

111

112

113

114

117

127

134

Study design and study population

A cohort study was carried out within the OpenSAFELY platform, which has been described previously.⁶ We used routinely-collected electronic data from primary care practices using TPP SystmOne software, covering approximately 40% of the population in England, linked at the individual patient level to NHS Secondary Uses Service (SUS) data on hospitalisations, and Office of National Statistics death registration data (from 2019 onwards). We selected all individuals discharged between 1st February and 30th December 2020 from a hospitalisation that lasted >1 day and where COVID-19 was coded as the primary diagnosis (based on the International Classification of Diseases (ICD)-10 codes U07.1 "COVID-19 - virus identified" and U07.2 "COVID-19 - virus not identified") and who were alive and under follow-up one week after discharge (to avoid a focus on hospital transfers and immediate readmissions/deaths). We excluded a small number of people with missing age, sex, or index of multiple deprivation, which are likely to indicate poor data quality. Two comparison groups were also selected: (i) people under follow-up in the general population in 2019, individually matched 5:1 to the COVID-19 group on age (within 3 years), sex, Sustainability and Transformation Plans (STP, a geographical area used as in NHS administration, of which there were 32 in our data), and calendar month (e.g. a patient discharged from a COVID-19 hospitalisation in April 2020 was matched to 5 individuals of the same age, sex and STP who were under follow-up in general practice on 1st April 2019); (ii) all individuals discharged from hospital in 2017-2019 where influenza was coded as the primary reason for hospitalisation and who were alive and under followup one week after discharge.

Outcomes and covariates

The outcomes were (i) time to first hospitalisation or death (composite outcome); (ii) all-cause mortality; and (iii) time to first cause-specific hospitalisation or death. Hospitalisations were

identified from linked SUS data. All-cause mortality was identified using date of death in the primary

care record so that deaths before 2019 (in the influenza group) could be included (as linked ONS

data were not available prior to 2019); concordance of death dates between primary care and linked

ONS data has been shown to be high. 16 Cause-specific outcomes were categorised based on ICD-10

codes into infections (ICD-10 codes beginning with "A"), cancers except non-melanoma skin cancer

119 (C, except C44), endocrine/nutritional/metabolic (E), mental health and cognitive (F, G30 and X60-

120 84), nervous system (G, except G30), circulatory (I), COVID-19/influenza/pneumonia/other lower

respiratory tract infections (J09-22, U07.1/2), other respiratory (J23-99), digestive (K),

musculoskeletal (M), genitourinary (N), and external causes (S-Y, except X60-84). For each of these,

the outcome was time to the earliest of hospitalisation with the relevant outcome listed as primary

diagnosis, or death with the relevant outcome listed as the underlying cause on the death

certificate.¹⁷ The influenza control group was restricted to those discharged in 2019 for analyses of

these cause-specific outcomes, because we did not have linked death registration data (and thus

cause of death) for earlier years.

128 Other covariates considered in the analysis were factors that might be associated with both risk of

severe COVID-19 and subsequent outcomes, namely age, sex, ethnicity, obesity, smoking status,

index of multiple deprivation quintile (derived from the patient's postcode at lower super output

area level), and comorbidities considered potential risk factors for severe COVID-19 outcomes (see

132 Table 1 and footnotes for full specification of covariate categories and comorbidities).

133 Information on all covariates was obtained by searching TPP SystmOne records for specific coded

data, based on a subset of SNOMED-CT mapped to Read version 3 codes. Covariates were identified

using data prior to the patient's hospital admission date (for the COVID-19 and influenza groups) or

the index date (for the matched control group, i.e. 1st day of the matched calendar month in 2019).

137 For the COVID-19 and influenza hospitalised groups, primary care data on ethnicity was

138 supplemented with information from the hospitalisation record, to improve completeness. All 139 codelists, along with detailed information on their compilation are available at 140 https://codelists.opensafely.org for inspection and re-use by the wider research community. 141 142 Statistical analysis Follow-up began on the 8th day after hospital discharge for the COVID-19 and influenza groups, and 143 on the 1st of the same calendar month in 2019, for the general population control group. Follow-up 144 145 ended at the first occurrence of the analysis-specific outcome, or the earliest relevant censoring date 146 for data availability/coverage for the outcome being analysed; the control groups were additionally 147 censored after the maximum follow-up time of the COVID-19 group (315 days). For outcomes 148 involving hospital admissions the administrative censoring date (for SUS data) was 30th December 2020; for outcomes involving cause of death, the administrative censoring date (for ONS mortality 149 150 data) was 11th March 2021; for the all-cause death outcome which was ascertained in primary care data, patients were censored at date of deregistration if they had left the TPP general practice 151 152 network. Cumulative incidence of the composite hospitalisation/death outcome and all-cause mortality were calculated using Kaplan-Meier methods. Hazard ratios comparing COVID-19 and 153 154 controls were estimated using Cox regression models. Separate models were fitted for the comparisons with matched 2019 general population controls (models stratified by matched set), and 155 156 with influenza controls (models adjusted for age, sex, STP and calendar month). The additional 157 covariates noted above were then added to the models. People with missing data on ethnicity, body 158 mass index or smoking were excluded from models that used these variables ("complete case 159 analysis", which is valid under the assumption that missingness is conditionally independent of the outcome); 18 imputation was not used because these variables were thought to be missing not at 160 random in primary care (e.g. smokers more likely to have smoking status recorded). Cumulative 161 incidence of cause-specific hospitalisation/death outcomes were calculated with deaths from other 162 causes treated as a competing risk. Hazard ratios for these outcomes were then estimated from a 163 164 Cox model targeting the cause-specific hazard, with deaths from competing risks censored.

The study was approved by the Health Research Authority (REC reference 20/LO/0651) and by the LSHTM Ethics Board (ref 21863).

165

166

167

168

170 **Results** 171 24,673 individuals discharged after a COVID-19 hospitalisation were included, alongside 123,362 172 matched controls from the 2019 general population, and 16,058 individuals discharged after 173 influenza hospitalisation in 2017-19 (Appendix Figure A1-A2). 174 At entry, the COVID-19 group had similar age and sex distribution to the general population groups 175 due to matching, but had younger median age and were more likely to be male than the influenza 176 group (Table 1). Body mass index, smoking and ethnicity data were 93-99% complete in all groups, 177 except that ethnicity was 25% missing in the matched control group (no hospital-based ethnicity 178 records were available for this group). The COVID-19 group were more likely to be obese, non-White 179 and less likely to be current smokers than both comparison groups. Pre-existing comorbidities were more common in both COVID-19 and influenza-discharged patients than general population 180 181 controls. COVID-19 patients had longer median duration of hospital stay and were more likely to 182 have received critical care during their admission than influenza patients. 183 Numbers of outcome events are shown in Appendix Table A1. Cumulative incidence of subsequent 184 hospital admission or death after study entry in the COVID-19 group was higher than in general population controls, but similar to that in the influenza group (cumulative incidence at 6 months = 185 186 34.8, 15.2 and 37.8% in the three groups respectively; fully adjusted HR = 2.23, 2.14-2.31 for COVID-19 vs general population; 0.94, 0.91-0.98 for COVID-19 vs influenza, Figures 1a, 2). Cumulative all-187 188 cause mortality was higher in the COVID-19 group than both the general population and influenza 189 groups (7.5, 1.4 and 4.9% at 6 months in the three groups respectively; fully adjusted HR = 4.97, 190 4.58-5.40 for COVID-19 vs general population; 1.73, 1.60-1.87 for COVID vs influenza, Figures 1b, 2). 191 To further explore this, causes of death were examined (appendix Table A2). A substantial 192 proportion of deaths in the COVID-19 group had COVID-19 listed as the underlying cause (500/2022, 24.7%), while in the influenza group ≤5 deaths were coded with influenza as the underlying cause. 193 194 Cumulative incidences of cause-specific hospital admissions or deaths are shown in Figure 3. After 195 adjustment for matching factors and other covariates, risks of all cause-specific outcomes were 196 substantially higher in COVID-19 groups than general population controls (Figure 4). Compared with 197 influenza patients, people in the COVID-19 group had similar or lower risk of admission or death 198 from most causes, but higher risks of admission/death from COVID-19/influenza/lower respiratory 199 tract infection (LRTI, adjusted HR 1.37, 1.22-1.54); in the post-COVID-19 group these outcomes were 200 dominated by codes for COVID-19 itself (515/1122 [46%] of hospitalisations and 342/368 [93%] of 201 deaths) and pneumonia (461/1122 [41%] of hospitalisations). The COVID-19 group also had higher 202 risks than the influenza group for mental health or cognitive outcomes (adjusted HR 1.36, 1.01-1.83). 203 This was further explored in a post-hoc analysis of specific outcomes within the mental health and 204 cognitive category (Table 2). Raised risks in the COVID-19 group appeared to be driven by dementia 205 hospitalisations/deaths (age/sex-adjusted HR 2.32, 1.48-3.64), particularly among those with pre-206 existing dementia at baseline (HR 2.47, 1.37-4.44) and/or resident in care homes (HR 2.53, 0.99-207 6.41). Of note, 129/161 dementia outcome events (80.1%) were deaths (rather than 208 hospitalisations). Higher rates of hospitalisations/deaths due to mood disorders, and 209 neurotic/stress-related/somatoform disorders were also observed in COVID-19 patients, but 210 confidence intervals were too wide to be conclusive.

Discussion

211

212

216

217

219

220

221

222

223

224

227

236

237

244

Key findings

213 Patients discharged from a COVID-19 hospitalisation had more than double the risk of hospitalisation 214 or death, and a 5-fold higher risk of all-cause mortality than controls from the general population, 215

after adjusting for baseline personal and clinical characteristics. Risks were higher for all categories

of disease-specific hospital admissions/deaths after a COVID-19 hospitalisation than in general

population controls. Most outcomes were similar between people discharged from a COVID-19

218 hospitalisation, and people discharged from an influenza hospitalisation in 2017-19, but the COVID-

19 group had higher subsequent all-cause mortality; higher rates of respiratory infection admissions

and deaths (predominantly COVID-19), and more adverse mental health and cognitive outcomes

(particularly deaths attributed to dementia among people with pre-existing dementia) compared

with the influenza group.

Findings in context of literature and explanations

A recent study of VA data on US veterans examined a wide range of diagnostic and other outcomes 225 226 in 30-day COVID-19 survivors, compared with the general VA population. 13 Among veterans where

COVID-19 had led to a hospitalisation, hazard ratios of every category of outcome were raised. This

228 concurs with findings from our study, despite different characteristics of the VA population. In the

229 UK, an earlier study found an 8-fold higher risk of death in post-acute COVID-19 patients compared with general population controls, and raised risks of respiratory disease, diabetes and cardiovascular 230

231 disease.¹⁵ Interestingly, recent data from Denmark suggest limited post-acute complications

following non-hospitalised COVID-19;19 this is in contrast to a recent study using US health insurance 232

233 data which found raised risks of a range of outcomes among a relatively young cohort with mostly

234 (92%) non-hospitalised COVID-19 disease, compared with both the general population and people

235 with a record of other viral lower respiratory tract infections.¹⁴

Our data showed that COVID-19 hospitalised patients were more likely to have baseline

comorbidities than general population controls, reflecting known associations between

comorbidities and risks of severe COVID-19 outcomes. Differences in outcomes between 238

239 hospitalised patients and general population controls might therefore reflect baseline differences

240 not fully captured in our adjustment models, and might also reflect a generic adverse effect of

241 hospitalisation.²⁰ This is supported by the more similar risks we observed when COVID-19 survivors

242 were compared with people who had experienced influenza hospitalisation. However, all-cause

243 mortality was substantially higher after COVID-19 compared with influenza. A guarter of deaths after

a COVID-19 hospitalisation had COVID-19 listed as the underlying cause, but it is not clear from our

245 data whether patients experienced specific complications after hospital discharge that were then

246 attributed to COVID-19.

247 Our analysis of cause-specific outcomes also suggested a disproportionate rate of dementia deaths

post-COVID-19, particularly among those with pre-existing dementia. Cognitive decline after 248

hospitalisation and critical illness have been previously described;^{21,22} acute COVID-19 and 249

250 associated hospital admission, social isolation, and medications may have accelerated progression of

patients' dementia; it is unclear whether post-discharge care was adequate for this vulnerable 251

252 group. However, it is possible that deaths where the underlying cause was recorded as dementia

253 may have been due to progression of underlying health problems following an acute illness as well

254 as difficulty in managing these due to dementia. Due to small numbers, we could not confirm

255 whether higher rates of mood disorders and neurotic/stress-related/somatoform disorders after

256 COVID-19 compared with influenza were due to chance, but a number of previous studies outside

257 the pandemic context have found that critical illness is associated with raised risks of depression,

258 anxiety and post-traumatic stress.²³⁻²⁵ It will be important to continue to monitor these outcomes as

259 more follow-up accumulates.

Strengths and Limitations

260

261

262

263

264

265266

267

268

269270

271

272

273

274

275

276

277

278

279

280

281 282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

We identified COVID-19 hospitalisations from a base population covering around 40% of the population of England, giving us high statistical power. We examined a broad range of hospitalisation and mortality outcomes, and were able to describe and adjust for a wide range of personal and clinical characteristics using rich primary care data.

However, our study has some limitations. We relied on ICD-10 codes entered as the primary reason for hospitalisation or underlying cause of death to define our cause-specific outcomes, but these fields may not have been used consistently.²⁶ In particular, there might have been a tendency for clinicians aware of a recent COVID-19 hospitalisation to code COVID-19 for a range of clinical complications, masking more specific sequelae. Outcomes were classified in broad categories to obtain an overview of post-COVID-19 disease patterns; more granular disease categories would be of future interest but will require more follow-up to maintain statistical power. Our main comparisons may have been affected by time-related factors. We compared post-COVID patients in 2020 with controls from 2019 and earlier; consultations for non-COVID-19 conditions in 2020 are known to have been subdued in the general population,²⁷ perhaps due to lockdown, or public reluctance to seek care, potentially affecting comparison with earlier years. On the other hand, patients with recent a COVID-19 hospitalisation may assume immunity from reinfection and be less reticent in seeking care than the general population. The comparison with influenza may also have been affected by seasonality, since the first wave of COVID-19 in England happened outside the typical influenza season. Lack of overlap in the data meant that we could not incorporate seasonal adjustment into our statistical models for this comparison; any confounding by seasonality is likely to have led to underestimation of hazard ratios comparing COVID-19 and influenza patients, since cases of the former were under-represented in the winter months (which typically confer higher health risks). We did not have detailed data on disease severity, though descriptive data showed that COVID-19 patients tended to have longer hospital stays and more critical care than those hospitalised for influenza. Finally, data were unavailable on new/emerging COVID-19 variants during the study period.

Conclusions

Patients surviving a COVID-19 hospitalisation were at substantially higher risk than the general population for a range of subsequent adverse outcomes over a period of up to 10 months' follow-up included in this study. Risks for most outcomes were broadly comparable to those experienced by influenza hospitalisation survivors prior to the pandemic, but in the period following hospital discharge COVID-19 patients had higher risks of all-cause mortality, readmission or death attributed to their initial infection, and adverse mental health and cognitive outcomes; in particular, among people with pre-existing dementia, we observed an excess of deaths where dementia was recorded as the underlying cause. These findings suggest a need for services to support and closely monitor people following discharge from hospital with COVID-19.

Contributors

302

303 304

305

306 307

308

309

310

311

312

313

314

315316

317318

319

320

321

322

323

324

325326

327

328

329

330

331332

333

334

335

336337

338339

340

341

342

343344

345

346

347

348349

350

351 352 KB, CTR, WJH led the study design. GH led on platform support. KB did the analysis and wrote the first draft. BG conceived the OpenSAFELY platform and the approach. BG and LS lead the project overall and are guarantors. SB led on software development. AM led on information governance. Other contributions were – data curation - CB, JP, JC, SH, SB, DE, PI and CEM; disease category conceptualisation and codelists - KB CTR BM CB JC CEM AJW HIM IJD HJC JP; statistical analysis code: KB, EW; ethical approvals - HJC EW LS BG; software - SB, DE, PI, AJW, WJH, CEM, CB, FH, JC; writing (reviewing and editing) - KB, CTR, CWG, LT, BM, AS, AM, RME, CEM, IJD, SJWE, LS, BG. All authors were involved in design and conceptual development and reviewed and approved the final manuscript.

Information Governance and Ethics

NHS England is the data controller; TPP is the data processor; and the key researchers on OpenSAFELY are acting on behalf of NHS England. OpenSAFELY is hosted within the TPP environment which is accredited to the ISO 27001 information security standard and is NHS IG Toolkit compliant;^{28,29} patient data are pseudonymised for analysis and linkage using industry standard cryptographic hashing techniques; all pseudonymised datasets transmitted for linkage onto OpenSAFELY are encrypted; access to the platform is via a virtual private network (VPN) connection, restricted to a small group of researchers who hold contracts with NHS England and only access the platform to initiate database queries and statistical models. All database activity is logged. No patient-level data leave the platform; only aggregate statistical outputs leave the platform environment following best practice for anonymisation of results such as statistical disclosure control for low cell counts.³⁰ The OpenSAFELY platform adheres to the data protection principles of the UK Data Protection Act 2018 and the EU General Data Protection Regulation (GDPR) 2016. In March 2020, the Secretary of State for Health and Social Care used powers under the UK Health Service (Control of Patient Information) Regulations 2002 (COPI) to require organisations to process confidential patient information for the purposes of protecting public health, providing healthcare services to the public and monitoring and managing the COVID-19 outbreak and incidents of exposure.31 Taken together, these provide the legal bases to link patient datasets on the OpenSAFELY platform. The study was approved by the Health Research Authority (REC reference 20/LO/0651) and by the LSHTM Ethics Board (ref 21863).

Declaration of interests

This work was jointly funded by UKRI, NIHR and Asthma UK-BLF [COV0076; MR/V015737/] and the Longitudinal Health and Wellbeing strand of the National Core Studies programme. The OpenSAFELY data science platform is funded by the Wellcome Trust. TPP provided technical expertise and infrastructure within their data centre pro bono in the context of a national emergency. BG has received research funding from the Laura and John Arnold Foundation, the NHS National Institute for Health Research (NIHR), the NIHR School of Primary Care Research, the NIHR Oxford Biomedical Research Centre, the Mohn-Westlake Foundation, NIHR Applied Research Collaboration Oxford and Thames Valley, the Wellcome Trust, the Good Thinking Foundation, Health Data Research UK, the Health Foundation, the World Health Organisation, UKRI, Asthma UK, the British Lung Foundation, and the Longitudinal Health and Wellbeing strand of the National Core Studies programme; he also receives personal income from speaking and writing for lay audiences on the misuse of science. LS reports grants from Wellcome, MRC, NIHR, UKRI, British Council, GSK, British Heart Foundation, and Diabetes UK outside this work. KB holds a Senior Research Fellowship from Wellcome (220283/Z/20/Z). CWG is supported by a Wellcome Intermediate Clinical Fellowship (201440/Z/16/Z). HIM is funded by the National Institute for Health Research (NIHR) Health Protection Research Unit in Immunisation, a partnership between Public Health England and LSHTM. EW holds grants from MRC. ID golds grants from NIHR and GSK. HF holds a UKRI fellowship. RME is funded by HDR UK (grant: MR/S003975/1) and MRC (grant: MC_PC 19065). The views expressed are

those of the authors and not necessarily those of the NIHR, NHS England, Public Health England or the Department of Health and Social Care. Funders had no role in the study design, collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.

Open access statement

This research was funded in whole or in part by the Wellcome Trust. For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript (AAM) version arising from this submission.

Data availability statement

All data were linked, stored and analysed securely within the OpenSAFELY platform https://opensafely.org/. Data include pseudonymized data such as coded diagnoses, medications and physiological parameters. No free text data are included. All code is shared openly for review and re-use under MIT open license (https://github.com/opensafely/post-admission-admissions-research). Detailed pseudonymised patient data is potentially re-identifiable and therefore not shared. We rapidly delivered the OpenSAFELY data analysis platform without prior funding to deliver timely analyses on urgent research questions in the context of the global Covid-19 health emergency: now that the platform is established we are developing a formal process for external users to request access in collaboration with NHS England; updates on this process are available on OpenSAFELY.org.

Patient and Public Involvement

Patients were not formally involved in developing this specific study design that was developed rapidly in the context of a global health emergency. We have developed a publicly available website https://opensafely.org/ through which we invite any patient or member of the public to contact us regarding this study or the broader OpenSAFELY project.

References

- 385 1. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. 2021.
- 386 https://covid19.who.int (accessed 12th May 2021).
- 2. Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection. *Ann Intern Med* 2020;
- 388 **173**(5): 362-7. doi: 10.7326/M20-3012.
- 389 3. Prieto-Alhambra D, Balló E, Coma E, Mora N, Aragón M, Prats-Uribe A, Fina F, Benítez M,
- Guiriguet C, Fàbregas M, Medina-Peralta M, Duarte-Salles T. Filling the gaps in the characterization
- of the clinical management of COVID-19: 30-day hospital admission and fatality rates in a cohort of
- 392 118 150 cases diagnosed in outpatient settings in Spain. Int J Epidemiol 2020; 49(6): 1930-9. doi:
- 393 10.1093/ije/dyaa190.
- 394 4. Clift AK, Coupland CAC, Keogh RH, Diaz-Ordaz K, Williamson E, Harrison EM, Hayward A,
- Hemingway H, Horby P, Mehta N, Benger J, Khunti K, Spiegelhalter D, Sheikh A, Valabhji J, Lyons RA,
- Robson J, Semple MG, Kee F, Johnson P, Jebb S, Williams T, Hippisley-Cox J. Living risk prediction
- algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults:
- national derivation and validation cohort study. *BMJ* 2020; **371**: m3731. doi: 10.1136/bmj.m3731.
- 399 5. Mathur R, Rentsch CT, Morton CE, Hulme WJ, Schultze A, MacKenna B, Eggo RM, Bhaskaran
- K, Wong AYS, Williamson EJ, Forbes H, Wing K, McDonald HI, Bates C, Bacon S, Walker AJ, Evans D, Inglesby P, Mehrkar A, Curtis HJ, DeVito NJ, Croker R, Drysdale H, Cockburn J, Parry J, Hester F,
- Harper S, Douglas IJ, Tomlinson L, Evans SJW, Grieve R, Harrison D, Rowan K, Khunti K, Chaturvedi N,
- 403 Smeeth L, Goldacre B. Ethnic differences in SARS-CoV-2 infection and COVID-19-related
- 404 hospitalisation, intensive care unit admission, and death in 17 million adults in England: an
- observational cohort study using the OpenSAFELY platform. *The Lancet* 2021; **397**(10286): 1711-24.
- 406 doi: 10.1016/S0140-6736(21)00634-6.
- 407 6. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, Curtis HJ, Mehrkar A,
- 408 Evans D, Inglesby P. OpenSAFELY: factors associated with COVID-19 death in 17 million patients.
- 409 Nature 2020: 1-11. doi: 10.1038/s41586-020-2521-4.
- Thou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu
- X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients
- 412 with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; **395**(10229): 1054-62.
- 413 doi: 10.1016/S0140-6736(20)30566-3.
- 8. Navaratnam AV, Gray WK, Day J, Wendon J, Briggs TWR. Patient factors and temporal trends
- 415 associated with COVID-19 in-hospital mortality in England: an observational study using
- administrative data. The Lancet Respiratory Medicine 2021; 9(4): 397-406. doi: 10.1016/S2213-
- 417 2600(20)30579-8.
- 418 9. Siemieniuk RA, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, Pardo-Hernandez H, Qasim
- 419 A, Martinez JPD, Rochwerg B, Lamontagne F, Han MA, Liu Q, Agarwal A, Agoritsas T, Chu DK, Couban
- 420 R, Cusano E, Darzi A, Devji T, Fang B, Fang C, Flottorp SA, Foroutan F, Ghadimi M, Heels-Ansdell D,
- 421 Honarmand K, Hou L, Hou X, Ibrahim Q, Khamis A, Lam B, Loeb M, Marcucci M, McLeod SL, Motaghi
- 422 S, Murthy S, Mustafa RA, Neary JD, Rada G, Riaz IB, Sadeghirad B, Sekercioglu N, Sheng L, Sreekanta
- 423 A, Switzer C, Tendal B, Thabane L, Tomlinson G, Turner T, Vandvik PO, Vernooij RW, Viteri-García A,
- 424 Wang Y, Yao L, Ye Z, Guyatt GH, Brignardello-Petersen R. Drug treatments for covid-19: living
- 425 systematic review and network meta-analysis. *BMJ* 2020; **370**: m2980. doi: 10.1136/bmj.m2980.
- 426 10. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, Cook JR, Nordvig
- 427 AS, Shalev D, Sehrawat TS, Ahluwalia N, Bikdeli B, Dietz D, Der-Nigoghossian C, Liyanage-Don N,
- 428 Rosner GF, Bernstein EJ, Mohan S, Beckley AA, Seres DS, Choueiri TK, Uriel N, Ausiello JC, Accili D,
- 429 Freedberg DE, Baldwin M, Schwartz A, Brodie D, Garcia CK, Elkind MSV, Connors JM, Bilezikian JP,
- 430 Landry DW, Wan EY. Post-acute COVID-19 syndrome. *Nat Med* 2021; **27**(4): 601-15. doi:
- 431 10.1038/s41591-021-01283-z.
- 432 11. Mazza MG, De Lorenzo R, Conte C, Poletti S, Vai B, Bollettini I, Melloni EMT, Furlan R, Ciceri
- 433 F, Rovere-Querini P, Benedetti F. Anxiety and depression in COVID-19 survivors: Role of
- inflammatory and clinical predictors. *Brain Behav Immun* 2020; **89**: 594-600. doi:
- 435 https://doi.org/10.1016/j.bbi.2020.07.037.
- 436 12. Xiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y, Dong W. Clinical sequelae of COVID-19 survivors in
- Wuhan, China: a single-centre longitudinal study. *Clin Microbiol Infect* 2021; **27**(1): 89-95. doi:
- 438 https://doi.org/10.1016/j.cmi.2020.09.023.

- 439 13. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequalae of COVID-
- 440 19. *Nature* 2021. doi: 10.1038/s41586-021-03553-9.
- 441 14. Daugherty SE, Guo Y, Heath K, Dasmariñas MC, Jubilo KG, Samranvedhya J, Lipsitch M,
- 442 Cohen K. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort
- 443 study. *BMJ* 2021; **373**: n1098. doi: 10.1136/bmj.n1098.
- 444 15. Ayoubkhani D, Khunti K, Nafilyan V, Maddox T, Humberstone B, Diamond I, Banerjee A. Post-
- covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ
- 446 2021; **372**: n693. doi: 10.1136/bmj.n693.
- 447 16. Gallagher AM, Dedman D, Padmanabhan S, Leufkens HGM, de Vries F. The accuracy of date
- of death recording in the Clinical Practice Research Datalink GOLD database in England compared
- with the Office for National Statistics death registrations. *Pharmacoepidemiol Drug Saf* 2019; **28**(5):
- 450 563-9. doi: 10.1002/pds.4747.
- 451 17. Office of National Statistics' Death Certification Advisory group. Guidance for doctors
- completing medical certificates of cause of death in England and Wales: Office of National Statistics,
- 453 2020.
- 454 18. White IR, Carlin JB. Bias and efficiency of multiple imputation compared with complete-case
- analysis for missing covariate values. *Stat Med* 2010; **29**(28): 2920-31. doi: 10.1002/sim.3944.
- 456 19. Lund LC, Hallas J, Nielsen H, Koch A, Mogensen SH, Brun NC, Christiansen CF, Thomsen RW,
- 457 Pottegård A. Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital
- 458 admission: a Danish population-based cohort study. The Lancet Infectious Diseases. doi:
- 459 10.1016/S1473-3099(21)00211-5.
- 460 20. Krumholz HM. Post-hospital syndrome--an acquired, transient condition of generalized risk.
- 461 *The New England journal of medicine* 2013; **368**(2): 100-2. doi: 10.1056/NEJMp1212324.
- 462 21. Pandharipande PP, Girard TD, Jackson JC, Morandi A, Thompson JL, Pun BT, Brummel NE,
- Hughes CG, Vasilevskis EE, Shintani AK, Moons KG, Geevarghese SK, Canonico A, Hopkins RO,
- 464 Bernard GR, Dittus RS, Ely EW. Long-Term Cognitive Impairment after Critical Illness. N Engl J Med
- 465 2013; **369**(14): 1306-16. doi: 10.1056/NEJMoa1301372.
- 466 22. Wilson RS, Hebert LE, Scherr PA, Dong X, Leurgens SE, Evans DA. Cognitive decline after
- hospitalization in a community population of older persons. *Neurology* 2012; **78**(13): 950-6. doi:
- 468 10.1212/WNL.0b013e31824d5894.
- 469 23. Nikayin S, Rabiee A, Hashem MD, Huang M, Bienvenu OJ, Turnbull AE, Needham DM. Anxiety
- 470 symptoms in survivors of critical illness: a systematic review and meta-analysis. Gen Hosp Psychiatry
- 471 2016; **43**: 23-9. doi: 10.1016/j.genhosppsych.2016.08.005.
- 472 24. Parker AM, Sricharoenchai T, Raparla S, Schneck KW, Bienvenu OJ, Needham DM.
- 473 Posttraumatic stress disorder in critical illness survivors: a metaanalysis. *Crit Care Med* 2015; **43**(5):
- 474 1121-9. doi: 10.1097/ccm.000000000000882.
- 475 25. Rabiee A, Nikayin S, Hashem MD, Huang M, Dinglas VD, Bienvenu OJ, Turnbull AE, Needham
- 476 DM. Depressive Symptoms After Critical Illness: A Systematic Review and Meta-Analysis. Crit Care
- 477 *Med* 2016; **44**(9): 1744-53. doi: 10.1097/ccm.000000000001811.
- 478 26. Amoretti MC, Lalumera E. COVID-19 as the underlying cause of death: disentangling facts
- and values. History and Philosophy of the Life Sciences 2021; 43(1): 4. doi: 10.1007/s40656-020-
- 480 00355-6.
- 481 27. Mansfield KE, Mathur R, Tazare J, Henderson AD, Mulick AR, Carreira H, Matthews AA,
- 482 Bidulka P, Gayle A, Forbes H, Cook S, Wong AYS, Strongman H, Wing K, Warren-Gash C, Cadogan SL,
- Smeeth L, Hayes JF, Quint JK, McKee M, Langan SM. Indirect acute effects of the COVID-19 pandemic
- on physical and mental health in the UK: a population-based study. The Lancet Digital Health 2021;
- 485 **3**(4): e217-e30. doi: 10.1016/S2589-7500(21)00017-0.
- 486 28. NHS Digital. BETA Data Security Standards. 2020. https://digital.nhs.uk/about-nhs-
- 487 digital/our-work/nhs-digital-data-and-technology-standards/framework/beta---data-security-
- 488 standards (accessed 6th August 2020).
- 489 29. NHS Digital. Data Security and Protection Toolkit. 2020. https://digital.nhs.uk/data-and-
- 490 information/looking-after-information/data-security-and-information-governance/data-security-
- 491 and-protection-toolkit (accessed 6th August 2020).
- 492 30. NHS Digital. ISB1523: Anonymisation Standard for Publishing Health and Social Care Data.
- 493 2020. https://digital.nhs.uk/data-and-information/information-standards/information-standards-
- 494 and-data-collections-including-extractions/publications-and-notifications/standards-and-

- 495 <u>collections/isb1523-anonymisation-standard-for-publishing-health-and-social-care-data</u> (accessed 496 6th August 2020).
- 497 31. Secretary of State for Health UK Government. Coronavirus (COVID-19): notification to 498 organisations to share information. 2020.
- 499 https://www.gov.uk/government/publications/coronavirus-covid-19-notification-of-data-
- 500 <u>controllers-to-share-information</u> (accessed 6th August 2020).

501

502

Table 1: Characteristics of patients hospitalised for COVID-19 and controls

		Hospitalised with COVID-19	Matched controls from 2019 general population	Hospitalised with influenza in 2017-19
N (%)		24673 (100.0)	123362 (100.0)	16058 (100.0)
	10.20	, ,	,	
Age (yrs)	18-39 40-49	2035 (8.2) 2756 (11.2)	10175 (8.2) 13780 (11.2)	2024 (12.6) 1462 (9.1)
	50-59	4679 (19.0)	23395 (19.0)	2126 (13.2)
	60-69	4602 (18.7)	23010 (18.7)	2653 (16.5)
	70-79	5034 (20.4)	25170 (20.4)	3492 (21.7)
	80+	5567 (22.6)	27832 (22.6)	4301 (26.8)
	Median (IQR)	66 (53-78)	66 (53-78)	69 (52-80)
Sex	Male Female	13733 (55.7) 10940 (44.3)	68662 (55.7) 54700 (44.3)	7097 (44.2) 8961 (55.8)
Body mass index (kg/m²)	Not obese	12710 (51.5) [54.8]	82908 (67.2) [72.7]	10065 (62.7) [67.4]
N (% of total)	30-34.9 (Obese class I)	5860 (23.8) [25.3]	20985 (17.0) [18.4]	2853 (17.8) [19.1]
[% among non-missing]	35-39.9 (Obese class II)	2819 (11.4) [12.2]	7069 (5.7) [6.2]	1271 (7.9) [8.5]
	≥40 (Obese class III)	1789 (7.3) [7.7]	3015 (2.4) [2.6]	737 (4.6) [4.9]
Constitution	Missing	1495 (6.1)	9385 (7.6)	1132 (7.0)
Smoking status	Never	10350 (41.9) [42.2]	52145 (42.3) [43.0]	5711 (35.6) [35.8]
N (% of total) [% among non-missing]	Former Current	12498 (50.7) [51.0] 1663 (6.7) [6.8]	52426 (42.5) [43.2] 16699 (13.5) [13.8]	7346 (45.7) [46.1] 2874 (17.9) [18.0]
[// uniong non missing]	Missing	162 (0.7)	2092 (1.7)	127 (0.8)
Ethnicity	White	19061 (77.3) [78.3]	80923 (65.6) [87.7]	14035 (87.4) [88.5]
N (% of total)	Mixed	313 (1.3) [1.3]	821 (0.7) [0.9]	121 (0.8) [0.8]
[% among non-missing]	South Asian	3457 (14.0) [14.2]	6727 (5.5) [7.3]	1242 (7.7) [7.8]
	Black	920 (3.7) [3.8]	2225 (1.8) [2.4]	251 (1.6) [1.6]
	Other <i>Missing</i>	590 (2.4) [2.4] 332 (1.3)	1572 (1.3) [1.7] 31094 (25.2)	211 (1.3) [1.3] 198 (1.2)
Index of Multiple Deprivation	1 (least deprived)	4622 (18.7)	25428 (20.6)	3282 (20.4)
	2	4743 (19.2)	25259 (20.5)	3251 (20.2)
	3	4678 (19.0)	23503 (19.1)	3272 (20.4)
	4	5183 (21.0)	24222 (19.6)	3133 (19.5)
	5 (most deprived)	5447 (22.1)	24950 (20.2)	3120 (19.4)
Care home resident	Yes	1197 (4.9)	1650 (1.3)	391 (2.4)
Length of hospital stay Any critical care	Median (IQR) Yes	7 (3-13) 2659 (10.8)	-	4 (2-9) 18 (0.1)
Comorbidities	. 65	2005 (20.0)		20 (0.2)
Hypertension		12132 (49.2)	48565 (39.4)	7550 (47.0)
Chronic respiratory disease		3841 (15.6)	9664 (7.8)	3588 (22.3)
Asthma	With no oral steroid use	3741 (15.2)	14364 (11.6)	2872 (17.9)
	With oral steroid use	1334 (5.4)	2375 (1.9)	1210 (7.5)
Chronic heart disease		5540 (22.5)	18285 (14.8)	3934 (24.5)
Diabetes	With HbA1c<58 mmol/mol	4727 (19.2)	14855 (12.0)	2443 (15.2)
	With HbA1c>=58 mmol/mol With no recent HbA1c	3124 (12.7)	5567 (4.5)	1426 (8.9)
	measure	402 (1.6)	1133 (0.9)	218 (1.4)
Cancer (non-haematological)	Diagnosed < 1 year ago	401 (1.6)	1044 (0.8)	316 (2.0)
	Diagnosed 1-4.9 years ago	708 (2.9)	2959 (2.4)	539 (3.4)
	Diagnosed ≥5 years ago	1622 (6.6)	7353 (6.0)	1167 (7.3)
Haematological malignancy	Diagnosed < 1 year ago	70 (0.3)	123 (0.1)	110 (0.7)
	Diagnosed 1-4.9 years ago	167 (0.7)	362 (0.3)	239 (1.5)
	Diagnosed ≥5 years ago	252 (1.0)	694 (0.6)	295 (1.8)
Reduced kidney function	Estimated GFR 30-60	4502 (18.2)	17986 (14.6)	3299 (20.5)
	Estimated GFR 15-<30	481 (1.9)	1313 (1.1)	350 (2.2)
	Estimated GFR <15 or dialysis	443 (1.8)	353 (0.3)	342 (2.1)
Chronic liver disease		414 (1.7)	901 (0.7)	222 (1.4)
Dementia		1677 (6.8)	4409 (3.6)	1198 (7.5)
Stroke		1835 (7.4)	4275 (3.5)	1057 (6.6)
Other neurological disease		861 (3.5)	1817 (1.5)	574 (3.6)
Organ transplant		173 (0.7)	168 (0.1)	189 (1.2) 78 (0.5)
Asplenia Rheum arthritis/ lupus /psoriasis		99 (0.4) 2132 (8.6)	242 (0.2) 7717 (6.3)	78 (0.5) 1408 (8.8)
cam aramidaj lupus / pauliasis		76 (0.3)	311 (0.3)	108 (0.7)

Note: Diabetes HbA1c category was determined according to the most recent glycated haemoglobin (HbA1c) recorded in the 15 months prior to the index date; other neurological disease was defined as motor neurone disease, myasthenia gravis, multiple sclerosis, Parkinson's disease, cerebral palsy, quadriplegia or hemiplegia, and progressive cerebellar disease; asplenia included splenectomy or a spleen dysfunction, including sickle cell disease; other immunosuppressive conditions was defined as permanent immunodeficiency ever diagnosed, or aplastic anaemia or temporary immunodeficiency recorded within the last year.


Table 2: Post-hoc analysis of specific hospitalisation/mortality outcomes within the mental health and cognitive category

	[events] rate per 1000	Age- and sex- adjusted hazard ratio for COVID-19 vs influenza groups (95% CI)	
	COVID-19 group	Influenza group	
Dementia (F00-F03, G30)	[134] 14.74 (12.45-17.46)	[27] 5.20 (3.57-7.58)	2.32 (1.48-3.64)
(among those with baseline dementia) (among those with no baseline dementia)	[102] 168.07 (138.43-204.07) [32] 3.77 (2.67-5.33)	[14] 59.72 (35.37-100.84) [13] 2.62 (1.52-4.52)	2.47 (1.37-4.44) 1.23 (0.63-2.42)
(among those resident in a care home) (among those not resident in a care home)	[56] 127.78 (98.34-166.04) [78] 9.02 (7.22-11.26)	[<=5] 55.14 (22.95-132.47) [22] 4.31 (2.84-6.55)	2.53 (0.99-6.41) 1.80 (1.08-2.98)
Delirium (F05)	[77] 8.47 (6.78-10.59)	[28] 5.39 (3.72-7.81)	1.10 (0.70-1.72)
Schizophrenia/schizotypal/ delusional disorders (F20-29)	[<=5] 0.22 (0.06-0.88)	[<=5] 0.77 (0.29-2.05)	0.20 (0.03-1.12)
Mood disorders (F30-39)	[19] 2.09 (1.33-3.28)	[<=5] 0.77 (0.29-2.05)	1.61 (0.54-4.79)
Neurotic/stress-related/ somatoform disorders (F40-48)	[13] 1.43 (0.83-2.46)	[<=5] 0.58 (0.19-1.79)	2.59 (0.71-9.52)
All except dementia (F05-F99)	[114] 12.54 (10.44-15.07)	[41] 7.90 (5.82-10.73)	1.12 (0.77-1.62)

510

Figure 1: Cumulative incidence of admission or death (composite outcome), and all-cause mortality in patients discharged from COVID-19 hospital admissions, influenza hospital admissions, and in matched general population controls

(a) Composite outcome of hospitalisation or death



(b) All-cause mortality





Figure 2: Hazard ratios comparing exposed (prior COVID-19 hospitalisation) and controls for risk of subsequent hospital admission or death (composite outcome) and all-cause mortality


vs 2019 general population controls	HR and 95% CI
Adj for matching factors	2.72 (2.64-2.81)
+ comorbidities	2.25 (2.18-2.32)
+ obesity/smoking*	2.21 (2.13-2.28)
+ IMD/ethnicity*	2.23 (2.14-2.31)
rs flu controls	
Adj for age, sex, geography	0.88 (0.85-0.91)
+ comorbidities	0.92 (0.88-0.95)
+ obesity/smoking*	0.94 (0.90-0.98)
+ IMD/ethnicity*	0.94 (0.91-0.98)
All-cause mortality	
vs 2019 general population controls	Int
Adj for matching factors	5.86 (5.50-6.26)
+ comorbidities	4.78 (4.45-5.12)
+ obesity/smoking* + IMD/ethnicity*	4.79 (4.45-5.15) 4.97 (4.58-5.40)
s flu controls	
Adj for age, sex, geography	1.63 (1.51-1.76)
+ comorbidities	1.65 (1.53-1.78)
+ obesity/smoking*	1.73 (1.60-1.87)
+ IMD/ethnicity*	1.73 (1.60-1.87)
.5 1 2	5 10 20

^{*}among those with complete data available (see Table 1)

Figure 3: Cumulative incidence of cause-specific admission/death in patients discharged from COVID-19 hospital admissions, influenza hospital admissions, and in matched general population controls



Note: For each sub-panel in (c), the outcome was defined as the first hospitalisation or death record with an ICD-10 code in the given category listed as the primary reason for hospitalisation/underlying cause of death. Deaths from other causes were treated as competing risks. In the influenza group, only patients entering the study in 2019 were included in analysis of cause-specific outcomes, as linked cause of death data were only available from 2019 onwards.



540 541

542

538

543 Appendix

544

Figure A1: Study flow chart




Figure A2: Distribution of entry dates for those in the COVID-19 hospitalised group, and the influenzahospitalised and matched general population comparison groups




Table A1: Distribution of first outcomes (hospital admission or death) among included individuals

	Hospitalised with COVID-19	Hospitalised with influenza in 2017-19*	Matched controls from 2019 general population
N		16058 (6689 in	
·	24673	2019*)	123362
Any hospitalisation or death (composite outcome)	6499 (26.3)	7788 (48.5)	16681 (13.5)
Deaths	2022 (8.2)	1513 (9.4)	3904 (3.2)
Cause-specific admissions/deaths			
(total [deaths])			
Other infections (ICD-10 codes beginning A)	391 [<=5] (1.6)	255 [<=5] (3.8)	569 [6] (0.5)
Cancers (C, ex C44)	566 [174] (2.3)	355 [60] (5.3)	1478 [242] (1.2)
Endocrine, nutritional and metabolic (E)	218 [29] (0.9)	98 [13] (1.5)	361 [28] (0.3)
Mental health and cognitive (F/G30/X60-84)	248 [111] (1.0)	68 [26] (1.0)	356 [149] (0.3)
Nervous system (G, ex G30)	240 [84] (1.0)	116 [21] (1.7)	467 [98] (0.4)
Circulatory (I)	1039 [180] (4.2)	511 [56] (7.6)	2256 [300] (1.8)
COVID-19/Influenza/LRTI (J09-22, U07.1/2)	1490+ [368+] (6.0)	497 [18] (7.4)	1169 [55] (0.9)
Other respiratory (J23-99)	670 [98] (2.7)	526 [40] (7.9)	812 [100] (0.7)
Digestive (K)	751 [36] (3.0)	433 [11] (6.5)	2728 [26] (2.2)
Musculoskeletal (M)	408 [9] (1.7)	292 [7] (4.4)	1669 [14] (1.4)
Genitourinary (N)	573 [18] (2.3)	287 [<=5] (4.3)	1292 [28] (1.0)
External (S-Y, ex X60-84)	566 [<=5] (2.3)	301 [<=5] (4.5)	1476 [16] (1.2)

Note: counts for cause specific deaths in square brackets are deaths which were not preceded by a previous hospitalisation in the same outcome category; these are the deaths that counted as outcome events in the cause-specific analysis, and not the total number of deaths from the given cause. *In the influenza group, only patients entering the study in 2019 were included in analysis of cause-specific outcomes, as linked cause of death data were only available from 2019 onwards. *In the COVID-19 group, 515/1122 (46%) hospitalisations in the COVID-19/Influenza/LRTI outcome category had COVID-19 codes (ICD-10 U07.1/2) and a further 461/1122 (41%) had pneumonia codes (J18) as the primary diagnosis; 342/368 deaths (93%) had COVID-19 as the underlying cause.

Table A2: Leading causes of death in COVID-19 and influenza groups

COVID-19 group, N (%) (2022 total deaths)			Influenza group, N (%) (558 total deaths*)		
COVID-19	500 (25)	Cancer	150 (27)		
Cancer	359 (18)	Circulatory diseases	112 (20)		
Circulatory diseases	339 (17)	Other respiratory (ICD 10 J23-99)	101 (18)		
Other respiratory (ICD 10 J23-99)	156 (8)	Mental health/cognitive	35 (6)		
Mental health/cognitive	150 (7)	Nervous system	32 (6)		
		(Influenza)	≤5 (<1%)		

*Only 558/1513 deaths in the influenza group are included in this table as the remainder (pre-2019) did not have cause of death data available (cause of death data were only available for 2019 onwards).